RIGLNasdaqPharmaceutical PreparationsFiscal year ends December 31
RIGEL PHARMACEUTICALS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$46.72+0.75 (+1.63%)
Close on Oct 19, 2026
- Market cap
- $914.31M
- P/E (TTM)
- 2.9
- Dividend yield
- –
Share price
+$18.78 (+67.22%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
RIGEL PHARMACEUTICALS INC grew revenue 3.3% to $276.79M over the twelve months to Jun 30, 2026. Operating income fell 16.8% to $87.05M, moving the operating margin from 39.0% to 31.5%.
Revenue
$276.79M
+3.3% vs. a year earlier
Operating income
$87.05M
-16.8% vs. a year earlier
EPS, diluted
$16.04
+196.5% vs. a year earlier
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $914.31M
- P/E ratio
- 2.9
- Price to sales
- 3.30
- Price to book
- 2.15
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $276.79M
- Net income
- $321.91M
- EPS, diluted
- $16.04
- Book value per share
- $21.74
- Diluted shares
- 20M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$276.79M+3.3% YoY
Gross profit
$252.95M+3.2% YoY
Operating income
$87.05M-16.8% YoY
Net income
$321.91M+229.1% YoY
EPS, diluted
$16.04+196.5% YoY
Free cash flow
–
Reported periodTrailing twelve months